Advisory · Immunology
Anti-inflammatory franchise replacements are driving urgent buy-side activity.
Ambrosia provides senior-led advisory for immunology licensing, M&A, and strategic partnerships — backed by a proprietary database of 350 verified immunology transactions.
Deal Landscape
What immunology transactions actually look like.
Verified Transactions
350
Median Upfront
$82M
Key Structure Insight
Biosimilar cliff exposure is accelerating mid-pharma acquisition timelines
Selected Work
Immunology·Novel bispecific — global licensing with milestone structure optimization
Immunology·Autoimmune platform — buy-side target identification for mid-pharma
Related Insights
Research relevant to immunology.
Discuss your immunology transaction.
We’ll meet you at peer level — anywhere in the world.